What is LeMaitre Vascular, Inc.'s earnings per share (EPS)?

LeMaitre Vascular, Inc. (LMAT) reported diluted earnings per share of $2.52 for fiscal year 2025. This represents a 30.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LeMaitre Vascular, Inc. (LMAT) Financials

LMAT

Trailing 12 months to June 30, 2026

Revenue $262.4M +11.8% YoY

Net Income $65.6M +39.4% YoY

EPS (Diluted) $2.85 +39.0% YoY

Free Cash Flow $73.8M +41.1% YoY

Market Cap $1.8B as of Sep 12, 2026

Price / Sales 7.0x on $262.4M revenue, trailing 12 months to June 30, 2026

Price / Earnings 28.1x on $65.6M net income, trailing 12 months to June 30, 2026

Price / Book 4.4x on $420.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LMAT SEC filings page.

LeMaitre Vascular, Inc. (LMAT) reported $262.4M in revenue over the twelve months to Jun 30, 2026, up 11.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LMAT FY2025 2026-08-29

LeMaitre’s dominant mechanic is margin expansion converting into cash, alongside a 2024 balance-sheet step-up that altered financing.

Gross margin climbed from 68.6% in FY2024 to 71.5% in FY2025 while operating margin reached its highest reported level, pointing to broad margin expansion rather than a below-the-line benefit. Free cash flow margin reached 29.8% while operating cash flow rose to $81.3M, indicating that reported earnings were accompanied by cash generation rather than being consumed by reinvestment.

Revenue grew 13.5% in FY2025 while operating income grew 30.0%, showing that incremental sales dropped through faster than costs—a fixed-cost absorption pattern, not merely top-line expansion.

Assets expanded 59.1% in FY2024 while liabilities expanded 338.7%, indicating that the year’s balance-sheet step-up was financed disproportionately through obligations rather than retained earnings. By FY2025, leverage had eased from its FY2024 peak while the 12.9x current ratio signaled substantial short-term asset coverage, so the financing shift did not create comparable near-term tightness.

Financial Health Signals

Financial Health Score 81/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of LeMaitre Vascular, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

LeMaitre Vascular, Inc. has an operating margin of 27.2%, meaning the company retains $27 of operating profit per $100 of revenue. This strong profitability earns a score of 89/100, reflecting efficient cost management and pricing power. This is up from 23.8% the prior year.

Growth

LeMaitre Vascular, Inc.'s revenue grew 13.5% year-over-year to $249.6M, a solid pace of expansion. This earns a growth score of 73/100.

Leverage

LeMaitre Vascular, Inc. has a moderate D/E ratio of 0.56. This balance of debt and equity financing earns a leverage score of 58/100.

Liquidity

With a current ratio of 12.89, LeMaitre Vascular, Inc. holds $12.89 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.

Cash Flow

LeMaitre Vascular, Inc. converts 29.8% of revenue into free cash flow ($74.5M). This strong cash generation earns a score of 89/100.

Returns

LeMaitre Vascular, Inc. earns a strong 14.7% return on equity (ROE), meaning it generates $15 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 77/100. This is up from 13.1% the prior year.

Altman Z-Score Safe

7.01

LeMaitre Vascular, Inc. scores 7.01, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.8B) relative to total liabilities ($222.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

LeMaitre Vascular, Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.41x

For every $1 of reported earnings, LeMaitre Vascular, Inc. generates $1.41 in operating cash flow ($81.3M OCF vs $57.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

13.10x

LeMaitre Vascular, Inc. earns $13.10 in operating income for every $1 of interest expense ($67.9M vs $5.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$70.4M

YoY+9.6%

QoQ+5.8%

5Y CAGR+11.6%

10Y CAGR+12.1%

LeMaitre Vascular, Inc. generated $70.4M in revenue in Q2 2026. This represents an increase of 9.6% from the same quarter a year earlier. Against the prior quarter it is up 5.8%.

EBITDA

$23.1M

YoY+22.7%

QoQ+13.1%

5Y CAGR+10.9%

10Y CAGR+17.2%

LeMaitre Vascular, Inc.'s EBITDA was $23.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.7% from the same quarter a year earlier. Against the prior quarter it is up 13.1%.

Net Income

$17.1M

YoY+23.7%

QoQ+8.7%

5Y CAGR+15.5%

10Y CAGR+20.7%

LeMaitre Vascular, Inc. reported $17.1M in net income in Q2 2026. This represents an increase of 23.7% from the same quarter a year earlier. Against the prior quarter it is up 8.7%.

EPS (Diluted)

$0.74

YoY+23.3%

QoQ+8.8%

5Y CAGR+13.1%

10Y CAGR+18.1%

LeMaitre Vascular, Inc. earned $0.74 per diluted share (EPS) in Q2 2026. This represents an increase of 23.3% from the same quarter a year earlier. Against the prior quarter it is up 8.8%.

Cash & Balance Sheet

Free Cash Flow

$13.7M

YoY-28.0%

QoQ+10.9%

5Y CAGR+10.0%

LeMaitre Vascular, Inc. generated $13.7M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 28.0% from the same quarter a year earlier. Against the prior quarter it is up 10.9%.

Cash & Debt

$26.6M

YoY-2.0%

QoQ-0.8%

5Y CAGR+4.3%

10Y CAGR-1.0%

LeMaitre Vascular, Inc. held $26.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Dividends Per Share

$0.25

YoY+25.0%

QoQ0.0%

5Y CAGR+17.8%

10Y CAGR+18.7%

LeMaitre Vascular, Inc. paid $0.25 per share in dividends in Q2 2026. This represents an increase of 25.0% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

23M

YoY+1.0%

QoQ+0.1%

5Y CAGR+1.1%

10Y CAGR+2.2%

LeMaitre Vascular, Inc. had 23M shares outstanding in Q2 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Margins & Returns

Gross Margin

72.1%

YoY+2.1pp

QoQ-0.6pp

5Y change+6.3pp

10Y change+3.5pp

LeMaitre Vascular, Inc.'s gross margin was 72.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Operating Margin

29.0%

YoY+3.8pp

QoQ+2.3pp

5Y change+1.7pp

10Y change+12.1pp

LeMaitre Vascular, Inc.'s operating margin was 29.0% in Q2 2026, reflecting core business profitability. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.

Net Margin

24.2%

YoY+2.8pp

QoQ+0.7pp

5Y change+3.8pp

10Y change+12.6pp

LeMaitre Vascular, Inc.'s net profit margin was 24.2% in Q2 2026, showing the share of revenue converted to profit. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.

Return on Equity

4.1%

YoY+0.3pp

QoQ+0.2pp

5Y change-0.4pp

10Y change+0.9pp

LeMaitre Vascular, Inc.'s ROE was 4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

R&D Spending

$4.8M

YoY+36.9%

QoQ+19.4%

LeMaitre Vascular, Inc. invested $4.8M in research and development in Q2 2026. This represents an increase of 36.9% from the same quarter a year earlier. Against the prior quarter it is up 19.4%.

Share Buybacks

$17K

YoY+325.0%

QoQ-96.3%

LeMaitre Vascular, Inc. spent $17K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 325.0% from the same quarter a year earlier. Against the prior quarter it is down 96.3%.

Capital Expenditures

$2.3M

YoY+72.4%

QoQ-16.9%

5Y CAGR+10.5%

LeMaitre Vascular, Inc. invested $2.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 72.4% from the same quarter a year earlier. Against the prior quarter it is down 16.9%.

LMAT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LMAT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$262.4M	$249.6M+13.5%	$219.9M+13.6%	$193.5M+19.7%	$161.7M+4.7%	$154.4M+19.4%	$129.4M+10.4%	$117.2M+11.0%	$105.6M+4.7%	$100.9M+13.1%	$89.2M+13.8%	$78.4M+10.2%	$71.1M+10.1%	$64.5M+13.8%	$56.7M-1.6%	$57.7M
Cost of Revenue	$71.1M	$71.1M+3.0%	$69.0M+3.8%	$66.4M+17.1%	$56.8M+7.0%	$53.0M+18.5%	$44.7M+19.7%	$37.4M+18.2%	$31.6M+4.8%	$30.2M+15.1%	$26.2M+8.4%	$24.2M+6.7%	$22.7M+16.6%	$19.4M+22.5%	$15.9M-9.1%	$17.5M
Gross Profit	$191.3M	$178.5M+18.3%	$150.9M+18.8%	$127.0M+21.1%	$104.9M+3.5%	$101.4M+19.8%	$84.6M+6.0%	$79.9M+8.0%	$73.9M+4.6%	$70.7M+12.3%	$62.9M+16.2%	$54.2M+11.8%	$48.4M+7.4%	$45.1M+10.4%	$40.9M+1.6%	$40.2M
R&D Expenses	$15.4M	$14.1M-9.7%	$15.7M-7.8%	$17.0M+27.6%	$13.3M+12.7%	$11.8M+16.9%	$10.1M+8.9%	$9.3M+13.2%	$8.2M+23.5%	$6.6M+8.1%	$6.1M+12.1%	$5.5M+17.3%	$4.7M-10.9%	$5.2M+3.0%	$5.1M+15.1%	$4.4M
SG&A Expenses	$44.3M	$42.0M+15.9%	$36.3M+13.9%	$31.8M+10.7%	$28.7M+12.7%	$25.5M+13.3%	$22.5M+18.1%	$19.1M+7.7%	$17.7M+4.0%	$17.0M+18.5%	$14.4M+2.5%	$14.0M+0.9%	$13.9M+10.4%	$12.6M+14.6%	$11.0M-2.3%	$11.2M
Operating Income	$77.3M	$67.9M+30.0%	$52.3M+42.3%	$36.7M+36.8%	$26.8M-26.3%	$36.4M+26.5%	$28.8M+35.9%	$21.2M-24.9%	$28.2M+33.7%	$21.1M+29.2%	$16.3M+41.9%	$11.5M+81.6%	$6.3M+40.3%	$4.5M+6.6%	$4.2M+14.9%	$3.7M
EBITDA	N/A	$78.3M+26.6%	$61.9M+33.8%	$46.2M+27.5%	$36.3M-23.7%	$47.5M+27.7%	$37.2M+39.8%	$26.6M-18.2%	$32.5M+29.3%	$25.2M+26.3%	$19.9M+33.7%	$14.9M+54.1%	$9.7M+32.3%	$7.3M+12.9%	$6.5M+13.0%	$5.7M
Interest Expense	$5.2M	$5.2M+2428.8%	$205K	$0	$0-100.0%	$2.2M+69.4%	$1.3M	$0-100.0%	$2K-90.5%	$21K+50.0%	$14K	N/A	$5K-58.3%	$12K+1100.0%	$1K	N/A
Income Tax	$19.1M	$17.4M+35.9%	$12.8M+37.0%	$9.4M+36.7%	$6.9M-7.1%	$7.4M+20.3%	$6.1M+63.8%	$3.7M-31.9%	$5.5M+40.0%	$3.9M-30.5%	$5.7M+54.2%	$3.7M+52.4%	$2.4M+113.6%	$1.1M-20.8%	$1.4M-11.6%	$1.6M
Net Income	$65.6M	$57.7M+31.1%	$44.0M+46.2%	$30.1M+46.1%	$20.6M-23.4%	$26.9M+26.8%	$21.2M+18.3%	$17.9M-21.8%	$22.9M+33.6%	$17.2M+62.2%	$10.6M+36.5%	$7.8M+98.2%	$3.9M+22.3%	$3.2M+24.5%	$2.6M+20.0%	$2.1M
EPS (Basic)	N/A	$2.55+30.1%	$1.96+44.1%	$1.36+44.7%	$0.94-26.0%	$1.27+21.0%	$1.05+15.4%	$0.91-22.9%	$1.18+29.7%	$0.91+59.6%	$0.57+29.5%	$0.44+83.3%	$0.24+14.3%	$0.21+23.5%	$0.17+21.4%	$0.14
EPS (Diluted)	$2.85	$2.52+30.6%	$1.93+44.0%	$1.34+44.1%	$0.93-25.6%	$1.25+20.2%	$1.04+18.2%	$0.88-22.1%	$1.13+31.4%	$0.86+56.4%	$0.55+31.0%	$0.42+82.6%	$0.23+15.0%	$0.20+25.0%	$0.16+23.1%	$0.13
Diluted Shares (Avg)	N/A	23M+0.7%	23M+1.6%	22M+1.1%	22M+3.2%	21M+4.9%	20M+0.8%	20M+0.4%	20M+1.0%	20M+4.1%	19M+5.1%	18M+7.7%	17M+7.9%	16M+0.8%	16M-2.2%	16M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$70.4M+9.6%	$66.6M+11.2%	$64.5M+15.7%	$61.0M+11.4%	$64.2M+15.0%	$59.9M+12.0%	$55.7M+14.0%	$54.8M+15.6%
Cost of Revenue	$19.6M+1.9%	$18.2M-1.6%	$18.3M+6.6%	$15.1M-14.5%	$19.3M+10.8%	$18.5M+9.7%	$17.1M	$17.6M+6.3%
Gross Profit	$50.8M+12.9%	$48.4M+16.8%	$46.2M+19.7%	$46.0M+23.6%	$45.0M+16.9%	$41.4M+13.0%	$38.6M+16.0%	$37.2M+20.6%
R&D Expenses	$4.8M+36.9%	$4.1M-0.9%	$3.5M-2.3%	$3.0M-18.8%	$3.5M-17.3%	$4.1M+0.1%	$3.6M	$3.7M-13.4%
SG&A Expenses	$11.1M+6.9%	$12.0M+14.9%	$10.4M+9.5%	$10.8M+20.3%	$10.4M+17.9%	$10.5M+16.4%	$9.5M	$8.9M+15.4%
Operating Income	$20.4M+26.4%	$17.8M+40.8%	$18.8M+46.5%	$20.3M+54.5%	$16.1M+12.3%	$12.6M+6.3%	$12.9M+25.9%	$13.1M+43.2%
EBITDA	$23.1M+22.7%	$20.4M+34.4%	$21.4M+40.4%	$22.9M+47.2%	$18.8M+12.1%	$15.2M+6.5%	$15.3M+20.7%	$15.6M+34.5%
Interest Expense	$1.3M+0.2%	$1.3M+0.8%	$1.3M+533.2%	$1.3M	$1.3M	$1.3M	$205K	$0
Income Tax	$5.1M+19.8%	$4.0M+23.6%	$4.7M+66.3%	$5.2M+52.8%	$4.3M+16.6%	$3.2M+11.0%	$2.8M	$3.4M+46.7%
Net Income	$17.1M+23.7%	$15.7M+42.4%	$15.5M+39.5%	$17.4M+55.8%	$13.8M+16.5%	$11.0M+11.4%	$11.1M+31.7%	$11.1M+48.5%
EPS (Basic)	$0.75+23.0%	$0.69+40.8%	$0.69+38.0%	$0.77+54.0%	$0.61+15.1%	$0.49+11.4%	$0.50+31.6%	$0.50+47.1%
EPS (Diluted)	$0.74+23.3%	$0.68+41.7%	$0.68+41.7%	$0.75+53.1%	$0.60+15.4%	$0.48+9.1%	$0.48+26.3%	$0.49+48.5%
Diluted Shares (Avg)	25M+7.2%	23M+0.6%	N/A	24M+6.8%	23M+0.7%	23M+1.5%	N/A	23M+1.6%

LMAT Balance Sheet

LMAT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$615.7M+11.6%	$551.8M+59.1%	$346.8M+11.7%	$310.5M+6.0%	$292.8M+15.8%	$252.8M+34.2%	$188.3M+23.0%	$153.1M+21.2%	$126.3M+23.9%	$101.9M+12.4%	$90.7M+11.3%	$81.5M+15.6%	$70.5M+11.8%	$63.1M+5.7%	$59.7M
Current Assets	$468.2M+16.4%	$402.2M+106.7%	$194.6M+20.3%	$161.7M+15.6%	$139.9M+48.4%	$94.3M+2.4%	$92.1M-2.0%	$94.0M+17.1%	$80.3M+36.1%	$59.0M+1.4%	$58.2M+19.7%	$48.6M+16.4%	$41.7M+6.6%	$39.1M-1.4%	$39.7M
Cash & Equivalents	$28.2M+10.3%	$25.6M+5.5%	$24.3M+26.8%	$19.1M+38.1%	$13.9M-48.2%	$26.8M+127.1%	$11.8M-55.2%	$26.3M+37.8%	$19.1M-21.4%	$24.3M-11.5%	$27.5M+46.9%	$18.7M+27.1%	$14.7M-10.6%	$16.4M-18.3%	$20.1M
Short-Term Investments	$330.9M+20.7%	$274.1M+239.2%	$80.8M+27.1%	$63.6M+13.3%	$56.1M+26116.8%	$214K-99.0%	$20.9M-3.6%	$21.7M-4.0%	$22.6M	$0	$0	$0	$0	$0	$0
Inventory	$34.4M-0.7%	$34.7M+11.4%	$31.1M+16.6%	$26.7M+5.5%	$25.3M-10.1%	$28.1M+22.1%	$23.0M+40.5%	$16.4M+33.5%	$12.3M-37.3%	$19.6M+28.8%	$15.2M-9.0%	$16.7M+26.1%	$13.3M+22.1%	$10.9M+35.7%	$8.0M
Accounts Receivable	$33.6M+11.8%	$30.1M+19.9%	$25.1M+13.7%	$22.0M+12.3%	$19.6M+0.4%	$19.6M+18.0%	$16.6M+5.4%	$15.7M+4.8%	$15.0M+13.7%	$13.2M+10.2%	$12.0M+10.8%	$10.8M+2.0%	$10.6M+17.0%	$9.0M+5.9%	$8.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M+65.1%	$40.0M+33.8%	$29.9M+25.3%	$23.8M+1.8%	$23.4M+31.7%	$17.8M+2.9%	$17.3M+15.0%	$15.0M+9.3%	$13.7M+15.4%	$11.9M
Total Liabilities	$222.2M+3.6%	$214.5M+338.9%	$48.9M+15.6%	$42.3M+9.4%	$38.7M-51.8%	$80.2M+99.6%	$40.2M+75.9%	$22.9M+38.1%	$16.6M+14.8%	$14.4M+12.5%	$12.8M-3.5%	$13.3M-4.6%	$13.9M+36.9%	$10.2M+33.9%	$7.6M
Current Liabilities	$36.3M+18.7%	$30.6M+2.4%	$29.9M+18.0%	$25.3M+16.1%	$21.8M-13.3%	$25.1M+20.6%	$20.9M+5.5%	$19.8M+49.8%	$13.2M+25.8%	$10.5M+1.1%	$10.4M+3.3%	$10.0M-1.8%	$10.2M+21.8%	$8.4M+28.4%	$6.5M
Non-Current Liabilities	$185.9M+1.0%	$183.9M+868.1%	$19.0M+12.1%	$16.9M+0.6%	$16.8M-69.4%	$55.1M+184.7%	$19.3M+525.2%	$3.1M-8.0%	$3.4M-14.7%	$3.9M+60.8%	$2.5M-24.4%	$3.2M-12.6%	$3.7M+108.7%	$1.8M+67.7%	$1.1M
Total Equity	$393.5M+16.7%	$337.3M+13.2%	$297.9M+11.1%	$268.2M+5.5%	$254.2M+47.3%	$172.6M+16.5%	$148.1M+13.7%	$130.2M+18.6%	$109.8M+25.5%	$87.5M+12.3%	$77.9M+14.2%	$68.2M+20.6%	$56.6M+6.9%	$52.9M+1.5%	$52.1M
Retained Earnings	$184.7M+27.3%	$145.1M+25.7%	$115.4M+18.1%	$97.8M+10.9%	$88.1M+24.9%	$70.6M+23.7%	$57.0M+24.4%	$45.8M+61.8%	$28.3M+84.8%	$15.3M+87.9%	$8.2M+151.3%	$3.2M+587.0%	-$667K+82.8%	-$3.9M+39.9%	-$6.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$640.5M+10.9%	$629.5M+13.2%	$615.7M+11.6%	$598.1M+58.6%	$577.6M+59.1%	$556.0M+57.1%	$551.8M+59.1%	$377.0M+12.9%
Current Assets	$488.3M+13.5%	$477.8M+17.1%	$468.2M+16.4%	$452.0M+99.0%	$430.1M+102.1%	$408.1M+101.1%	$402.2M+106.7%	$227.1M+24.7%
Cash & Equivalents	$26.6M-2.0%	$26.9M+6.0%	$28.2M+10.3%	$25.5M+21.4%	$27.2M+22.0%	$25.3M-4.7%	$25.6M+5.5%	$21.0M+16.3%
Short-Term Investments	$349.6M+19.6%	$340.4M+22.8%	$330.9M+20.7%	$317.6M+208.6%	$292.3M+221.8%	$277.2M+239.3%	$274.1M+239.2%	$102.9M+30.3%
Inventory	$35.0M+4.5%	$34.9M+2.8%	$34.4M-0.7%	$36.3M+7.4%	$33.5M-3.0%	$33.9M+8.9%	$34.7M+11.4%	$33.8M+19.3%
Accounts Receivable	$35.7M-2.3%	$35.8M+1.9%	$33.6M+11.8%	$32.4M+0.5%	$36.5M+18.5%	$35.1M+16.1%	$30.1M+19.9%	$32.3M+35.1%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%	$65.9M0.0%
Total Liabilities	$220.2M+2.5%	$222.9M+6.9%	$222.2M+3.6%	$219.1M+376.9%	$214.9M+393.5%	$208.4M+358.6%	$214.5M+338.9%	$46.0M+1.3%
Current Liabilities	$29.9M-2.9%	$33.4M+34.9%	$36.3M+18.7%	$33.3M+13.4%	$30.8M+21.1%	$24.7M-7.7%	$30.6M+2.4%	$29.3M+1.1%
Non-Current Liabilities	$190.3M+3.4%	$189.5M+3.2%	$185.9M+1.0%	$185.9M+1019.1%	$184.1M+917.0%	$183.7M+885.2%	$183.9M+868.1%	$16.6M+1.6%
Total Equity	$420.3M+15.9%	$406.6M+17.0%	$393.5M+16.7%	$378.9M+14.5%	$362.7M+13.5%	$347.6M+12.7%	$337.3M+13.2%	$331.1M+14.7%
Retained Earnings	$206.0M+28.1%	$194.7M+28.4%	$184.7M+27.3%	$173.7M+26.3%	$160.8M+23.8%	$151.6M+24.5%	$145.1M+25.7%	$137.5M+24.9%

Not reported in any period shown, so not listed: Long-Term Debt.

LMAT Cash Flow Statement

LMAT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$83.0M	$81.3M+84.1%	$44.1M+20.1%	$36.8M+44.8%	$25.4M-27.7%	$35.1M+0.9%	$34.8M+145.4%	$14.2M-27.3%	$19.5M-14.7%	$22.9M+35.3%	$16.9M+47.7%	$11.4M+107.5%	$5.5M+2.3%	$5.4M+14.1%	$4.7M+49.0%	$3.2M
Depreciation & Amortization	N/A	$10.4M+8.4%	$9.6M+1.0%	$9.5M+0.9%	$9.4M-14.8%	$11.1M+31.9%	$8.4M+55.0%	$5.4M+25.3%	$4.3M+6.6%	$4.1M+12.9%	$3.6M+5.8%	$3.4M+1.8%	$3.3M+19.4%	$2.8M+25.0%	$2.2M+9.7%	$2.0M
Stock-Based Compensation	N/A	$7.8M+19.2%	$6.6M+23.5%	$5.3M+27.5%	$4.2M+19.9%	$3.5M+15.1%	$3.0M+14.4%	$2.6M+12.5%	$2.3M+4.1%	$2.3M+34.3%	$1.7M+18.0%	$1.4M+9.4%	$1.3M+3.9%	$1.3M+3.3%	$1.2M+10.6%	$1.1M
Capital Expenditures	$9.2M	$6.8M-2.6%	$7.0M-4.2%	$7.3M+125.0%	$3.2M-33.9%	$4.9M+63.7%	$3.0M-20.7%	$3.8M+23.1%	$3.1M-52.4%	$6.4M+125.9%	$2.8M+25.0%	$2.3M+93.6%	$1.2M-57.0%	$2.7M+126.1%	$1.2M-40.2%	$2.0M
Free Cash Flow	$73.8M	$74.5M+100.4%	$37.2M+26.0%	$29.5M+33.1%	$22.1M-26.7%	$30.2M-5.0%	$31.8M+205.4%	$10.4M-36.7%	$16.5M0.0%	$16.5M+17.0%	$14.1M+53.4%	$9.2M+111.3%	$4.3M+63.4%	$2.7M-24.4%	$3.5M+205.7%	$1.1M
Investing Cash Flow	-$68.5M	-$64.9M+67.5%	-$200.1M-709.7%	-$24.7M-138.3%	-$10.4M+83.0%	-$61.1M-15.5%	-$52.9M-119.5%	-$24.1M-241.6%	-$7.1M+75.6%	-$29.0M-68.3%	-$17.2M	N/A	N/A	-$6.2M-19.0%	-$5.2M-185.3%	-$1.8M
Financing Cash Flow	-$14.8M	-$14.5M-109.2%	$158.1M+2317.1%	-$7.1M+22.8%	-$9.2M-167.4%	$13.7M-57.4%	$32.2M+795.7%	-$4.6M-4.7%	-$4.4M-5620.0%	$80K+103.1%	-$2.6M	N/A	N/A	-$961K+69.6%	-$3.2M+16.9%	-$3.8M
Dividends Paid	$20.5M	$18.1M+25.9%	$14.4M+15.5%	$12.4M+13.3%	$11.0M+17.7%	$9.3M+21.3%	$7.7M+14.2%	$6.7M+23.7%	$5.4M+30.3%	$4.2M+25.8%	$3.3M+16.8%	$2.8M+23.3%	$2.3M+25.6%	$1.8M+21.1%	$1.5M+22.7%	$1.2M
Share Buybacks	$1.7M	$1.8M+5.9%	$1.7M+101.5%	$853K+32.9%	$642K-20.0%	$802K+40.7%	$570K-16.5%	$683K-7.8%	$741K-4.8%	$778K+150.2%	$311K+16.9%	$266K+26.1%	$211K-43.4%	$373K-81.5%	$2.0M-8.7%	$2.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$16.0M-21.3%	$15.1M+67.0%	$23.2M+52.5%	$28.8M+101.9%	$20.3M+110.8%	$9.0M+78.2%	$15.2M+41.3%	$14.2M+20.5%
Depreciation & Amortization	$2.7M+0.5%	$2.6M+2.8%	$2.6M+7.8%	$2.6M+7.7%	$2.6M+11.1%	$2.6M+7.1%	$2.4M-1.1%	$2.4M+1.3%
Stock-Based Compensation	$1.9M-0.5%	$2.1M+2.2%	N/A	$1.7M+8.1%	$1.9M+20.8%	$2.0M+27.1%	N/A	$1.6M+22.6%
Capital Expenditures	$2.3M+72.4%	$2.8M+101.2%	$1.8M-13.1%	$2.3M+36.6%	$1.3M-28.5%	$1.4M+0.9%	$2.0M+59.8%	$1.7M+58.6%
Free Cash Flow	$13.7M-28.0%	$12.3M+60.8%	$21.4M+62.7%	$26.5M+110.6%	$18.9M+144.6%	$7.7M+106.9%	$13.1M+38.8%	$12.6M+16.8%
Investing Cash Flow	-$11.1M+32.2%	-$13.1M-203.7%	-$16.8M+90.3%	-$27.4M-113.4%	-$16.3M-48.6%	-$4.3M-83.0%	-$173.9M-7590.9%	-$12.9M-30.6%
Financing Cash Flow	-$5.1M-82.8%	-$3.2M+38.6%	-$3.6M-102.2%	-$3.0M+6.3%	-$2.8M+3.7%	-$5.2M-13533.3%	$164.1M+6208.7%	-$3.1M-0.8%
Dividends Paid	$5.7M+26.5%	$5.7M+26.4%	$4.5M+26.0%	$4.5M+26.1%	$4.5M+25.8%	$4.5M+25.9%	$3.6M+15.5%	$3.6M+15.4%
Share Buybacks	$17K+325.0%	$460K-23.5%	$1.2M-10.1%	$0-100.0%	$4K-42.9%	$601K+67.9%	$1.4M+102.8%	$1K-80.0%

LMAT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LMAT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	71.5%+2.9pp	68.6%+3.0pp	65.7%+0.8pp	64.9%-0.8pp	65.6%+0.2pp	65.4%-2.7pp	68.1%-1.9pp	70.0%0.0pp	70.1%-0.5pp	70.6%+1.5pp	69.1%+1.0pp	68.1%-1.8pp	69.9%-2.1pp	72.0%+2.3pp	69.7%
Operating Margin	27.2%+3.4pp	23.8%+4.8pp	19.0%+2.4pp	16.6%-7.0pp	23.6%+1.3pp	22.3%+4.2pp	18.1%-8.6pp	26.7%+5.8pp	20.9%+2.6pp	18.3%+3.6pp	14.7%+5.8pp	8.9%+1.9pp	7.0%-0.5pp	7.5%+1.1pp	6.4%
Net Margin	23.1%+3.1pp	20.0%+4.5pp	15.6%+2.8pp	12.7%-4.7pp	17.4%+1.0pp	16.4%+1.1pp	15.3%-6.4pp	21.7%+4.7pp	17.0%+5.2pp	11.9%+2.0pp	9.9%+4.4pp	5.5%+0.6pp	5.0%+0.4pp	4.5%+0.8pp	3.7%
Return on Equity	14.7%+1.6pp	13.1%+2.9pp	10.1%+2.4pp	7.7%-2.9pp	10.6%-1.7pp	12.3%+0.2pp	12.1%-5.5pp	17.6%+2.0pp	15.7%+3.6pp	12.1%+2.1pp	10.0%+4.2pp	5.7%+0.1pp	5.7%+0.8pp	4.9%+0.8pp	4.1%
Return on Assets	9.4%+1.4pp	8.0%-0.7pp	8.7%+2.1pp	6.6%-2.6pp	9.2%+0.8pp	8.4%-1.1pp	9.5%-5.5pp	15.0%+1.4pp	13.6%+3.2pp	10.4%+1.8pp	8.6%+3.8pp	4.8%+0.3pp	4.5%+0.5pp	4.1%+0.5pp	3.6%
Current Ratio	12.89-0.2x	13.14+6.6x	6.51+0.1x	6.390.0x	6.41+2.7x	3.75-0.7x	4.42-0.3x	4.76-1.3x	6.09+0.5x	5.630.0x	5.61+0.8x	4.84+0.8x	4.08-0.6x	4.66-1.4x	6.07
Debt-to-Equity	0.56-0.1x	0.64+0.5x	0.160.0x	0.160.0x	0.15-0.3x	0.47+0.2x	0.27+0.1x	0.180.0x	0.150.0x	0.160.0x	0.160.0x	0.19-0.1x	0.25+0.1x	0.190.0x	0.15
Asset Turnover	0.410.0x	0.40-0.2x	0.560.0x	0.520.0x	0.530.0x	0.51-0.1x	0.62-0.1x	0.69-0.1x	0.80-0.1x	0.870.0x	0.860.0x	0.870.0x	0.920.0x	0.90-0.1x	0.97
FCF Margin	29.8%+12.9pp	16.9%+1.7pp	15.2%+1.5pp	13.7%-5.9pp	19.6%-5.0pp	24.6%+15.7pp	8.9%-6.7pp	15.6%-0.7pp	16.3%+0.5pp	15.8%+4.1pp	11.7%+5.6pp	6.1%+2.0pp	4.1%-2.1pp	6.2%+4.2pp	2.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	72.1%+2.1pp	72.7%+3.5pp	71.7%+2.4pp	75.3%+7.5pp	70.0%+1.1pp	69.2%+0.6pp	69.3%+1.2pp	67.8%+2.8pp
Operating Margin	29.0%+3.8pp	26.7%+5.6pp	29.2%+6.2pp	33.3%+9.3pp	25.1%-0.6pp	21.1%-1.1pp	23.1%+2.2pp	24.0%+4.6pp
Net Margin	24.2%+2.8pp	23.6%+5.2pp	24.1%+4.1pp	28.4%+8.1pp	21.4%+0.3pp	18.4%-0.1pp	20.0%+2.7pp	20.3%+4.5pp
Return on Equity	4.1%+0.3pp	3.9%+0.7pp	4.0%+0.6pp	4.6%+1.2pp	3.8%+0.1pp	3.2%0.0pp	3.3%+0.5pp	3.4%+0.8pp
Return on Assets	2.7%+0.3pp	2.5%+0.5pp	2.5%+0.5pp	2.9%0.0pp	2.4%-0.9pp	2.0%-0.8pp	2.0%-0.4pp	2.9%+0.7pp
Current Ratio	16.31+2.4x	14.32-2.2x	12.89-0.2x	13.58+5.8x	13.96+5.6x	16.49+8.9x	13.14+6.6x	7.74+1.5x
Debt-to-Equity	0.52-0.1x	0.55-0.1x	0.56-0.1x	0.58+0.4x	0.59+0.5x	0.60+0.5x	0.64+0.5x	0.140.0x
Asset Turnover	0.110.0x	0.110.0x	0.100.0x	0.100.0x	0.110.0x	0.110.0x	0.100.0x	0.150.0x
FCF Margin	19.4%-10.1pp	18.5%+5.7pp	33.2%+9.6pp	43.4%+20.4pp	29.5%+15.6pp	12.8%+5.9pp	23.6%+4.2pp	22.9%+0.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
LeMaitre Vascular, Inc. LMAT	FY2025	$249.6M	$57.7M	23.1%	$1.8B	81/100
DENTSPLY SIRONA Inc. XRAY	FY2025	$3.7B	-$598.0M	-16.3%	$2.1B	30/100
ICU Medical Inc ICUI	FY2025	$2.2B	$732K	0.0%	$3.9B	36/100
Envista Holdings Corporation NVST	FY2025	$2.7B	$47.0M	1.7%	$4.2B	43/100
Teleflex Incorporated TFX	FY2025	$2.0B	-$905.6M	-45.5%	$5.6B	48/100
Bausch + Lomb Corporation BLCO	FY2025	$5.1B	-$360.0M	-7.1%	$6.3B	37/100

Where LeMaitre Vascular, Inc. Ranks

Frequently Asked Questions

What is LeMaitre Vascular, Inc.'s annual revenue?

LeMaitre Vascular, Inc. (LMAT) reported $249.6M in total revenue for fiscal year 2025. This represents a 13.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is LeMaitre Vascular, Inc.'s revenue growing?

LeMaitre Vascular, Inc. (LMAT) revenue grew by 13.5% year-over-year, from $219.9M to $249.6M in fiscal year 2025.

Is LeMaitre Vascular, Inc. profitable?

Yes, LeMaitre Vascular, Inc. (LMAT) reported a net income of $57.7M in fiscal year 2025, with a net profit margin of 23.1%.

What is LeMaitre Vascular, Inc.'s EBITDA?

LeMaitre Vascular, Inc. (LMAT) had EBITDA of $78.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is LeMaitre Vascular, Inc.'s gross margin?

LeMaitre Vascular, Inc. (LMAT) had a gross margin of 71.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is LeMaitre Vascular, Inc.'s operating margin?

LeMaitre Vascular, Inc. (LMAT) had an operating margin of 27.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is LeMaitre Vascular, Inc.'s net profit margin?

LeMaitre Vascular, Inc. (LMAT) had a net profit margin of 23.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does LeMaitre Vascular, Inc. pay dividends?

Yes, LeMaitre Vascular, Inc. (LMAT) paid $0.80 per share in dividends during fiscal year 2025.

What is LeMaitre Vascular, Inc.'s return on equity (ROE)?

LeMaitre Vascular, Inc. (LMAT) has a return on equity of 14.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is LeMaitre Vascular, Inc.'s free cash flow?

LeMaitre Vascular, Inc. (LMAT) generated $74.5M in free cash flow during fiscal year 2025. This represents a 100.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is LeMaitre Vascular, Inc.'s operating cash flow?

LeMaitre Vascular, Inc. (LMAT) generated $81.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are LeMaitre Vascular, Inc.'s total assets?

LeMaitre Vascular, Inc. (LMAT) had $615.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are LeMaitre Vascular, Inc.'s capital expenditures?

LeMaitre Vascular, Inc. (LMAT) invested $6.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does LeMaitre Vascular, Inc. spend on research and development?

LeMaitre Vascular, Inc. (LMAT) invested $14.1M in research and development during fiscal year 2025.

Does LeMaitre Vascular, Inc. buy back shares?

Yes, LeMaitre Vascular, Inc. (LMAT) spent $1.8M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does LeMaitre Vascular, Inc. have outstanding?

LeMaitre Vascular, Inc. (LMAT) had 23M shares outstanding as of fiscal year 2025.

What is LeMaitre Vascular, Inc.'s current ratio?

LeMaitre Vascular, Inc. (LMAT) had a current ratio of 12.89 as of fiscal year 2025, which is generally considered healthy.

What is LeMaitre Vascular, Inc.'s debt-to-equity ratio?

LeMaitre Vascular, Inc. (LMAT) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is LeMaitre Vascular, Inc.'s return on assets (ROA)?

LeMaitre Vascular, Inc. (LMAT) had a return on assets of 9.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is LeMaitre Vascular, Inc.'s P/E ratio?

LeMaitre Vascular, Inc. (LMAT) trades at 28.1x earnings, its market capitalization divided by net income of $65.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.8B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is LeMaitre Vascular, Inc.'s price-to-sales ratio?

LeMaitre Vascular, Inc. (LMAT) trades at 7.0x sales, its market capitalization divided by revenue of $262.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is LeMaitre Vascular, Inc.'s Altman Z-Score?

LeMaitre Vascular, Inc. (LMAT) has an Altman Z-Score of 7.01, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is LeMaitre Vascular, Inc.'s Piotroski F-Score?

LeMaitre Vascular, Inc. (LMAT) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LeMaitre Vascular, Inc.'s earnings high quality?

LeMaitre Vascular, Inc. (LMAT) has an earnings quality ratio of 1.41x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can LeMaitre Vascular, Inc. cover its interest payments?

LeMaitre Vascular, Inc. (LMAT) has an interest coverage ratio of 13.10x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is LeMaitre Vascular, Inc.?

LeMaitre Vascular, Inc. (LMAT) scores 81 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.